Related Experiment Video
Updated: Sep 16, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Mid-Cavitary Obstruction in Hypertrophic Cardiomyopathy (HCM): A Rare Case Report and Management Approach
Rajeev Bharadwaj1, Deb Boruah1, Bhupen Barman1
1All India Institute of Medical Sciences, Guwahati, India.
Insights
Hypertrophic cardiomyopathy with mid-cavitary obstruction (MCO) is a serious condition. Early recognition and conservative beta-blocker therapy can improve symptoms in patients with MCO.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Medical Case Reports
Background:
- Hypertrophic cardiomyopathy (HCM) affects approximately 10% of patients with mid-cavitary obstruction (MCO).
- MCO is linked to severe outcomes, including sudden cardiac death and heart failure.
- Patients with MCO face risks of apical aneurysms, thromboembolism, and arrhythmias.
Purpose of the Study:
- To present a case of hypertrophic cardiomyopathy with mid-cavitary obstruction.
- To discuss the diagnosis and management of this uncommon condition.
- To highlight unique treatment considerations for MCO.
Main Methods:
- Case presentation of a 43-year-old male with type 2 diabetes mellitus.
- Diagnosis confirmed via cardiac MRI with gadolinium contrast, revealing significant MCO without left ventricular outflow tract obstruction.
- Assessment of scar burden and absence of other high-risk factors.
Main Results:
- The patient presented with dyspnea and palpitations.
- Cardiac MRI showed significant mid-cavitary obstruction (27% scar burden) but no left ventricular outflow tract obstruction.
- Conservative treatment with oral beta-blockers led to symptomatic improvement.
Conclusions:
- Early recognition of MCO in HCM is crucial for appropriate management.
- Conservative beta-blocker therapy can be effective in improving symptoms.
- Personalized treatment is essential given the high-risk nature of MCO.
Abstract:
Hypertrophic cardiomyopathy (HCM) with mid-cavitary obstruction (MCO) is an uncommon condition affecting approximately 10% of HCM patients which is associated with serious outcomes, including sudden cardiac death and heart failure. We present the case of a 43-year-old male with type 2 diabetes mellitus who experienced worsening dyspnea and palpitations, leading to the diagnosis of HCM with MCO without outlet obstruction. Cardiac MRI with gadolinium contrast reveals significant mid-cavitary obstruction without left ventricular outflow tract obstruction with a scar burden of 27% and the absence of other high-risk factors such as apical aneurysm and NSVT runs on Holter monitoring. The patient was treated conservatively with the oral beta-blocker therapy, resulting in symptomatic improvement. Given the high risk of an adverse outcome, it is crucial to recognise MCO early and provide the appropriate treatment. This case report discusses the presentation, diagnosis, and management of a patient with HCM and mid-cavitary obstruction, highlighting the unique treatment considerations associated with this condition.
Take Home Message:
Mid-cavitary obstruction (MCO) in hypertrophic cardiomyopathy (HCM) is associated with high-risk outcomes of sudden cardiac death and heart failure.While beta-blockers can improve symptoms in many MCO patients, treatment should be personalized based on the symptom severity and risk factors.Patients with MCO are at risk of complications like apical aneurysms, thromboembolism, and arrhythmias.
More Related Videos
14:39Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
Published on: April 21, 2014
08:42Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy